Gilead reports $5.8 billion in sales of hepatitis C drug

July 24, 2014 1:05 AM

16 0

Amid concerns over the high cost of its new treatment for hepatitis C, drugmaker Gilead Sciences Inc. reported $5.8 billion in sales for its blockbuster Sovaldi drug in the first half of 2014.

The successful product launch boosted Gilead's second-quarter results released Wednesday, but the drug's price tag of $1,000 per pill continues to upset lawmakers, health insurers and state Medicaid programs worried about the negative effect on healthcare costs.

Read more

To category page